home chevron_right R&D chevron_right Technology

Technology

Three proprietary & differentiated technology platforms enablethe production of pipelines & novel E3L platforms in a persistent & organized manner

Bifunctional degrader pipelines
Novel E3L platforms / Molecular glues

SpeedUPP™

PROTAC Hit to Candidate : 2 ~ 2.5yrs
Early lead cmpds
Massive in vivo tests / Lead Opt.
Candidate cmpd
  • Enhance a chance to obtain lead compound with favorable drug-like properties
  • Develop bifunctional degrader pipelines in a prompt manner
    • Degrader designing know-how derived from our experiences of designing/synthesizing/assaying 4,000+ degraders enables us to produce effective degrader compound with high hit ratio
    • 30+ seasoned medicinal chemists facilitate prompt degrader synthesis.
    • Our in-house luciferase-based live cell assay platform with the capability to develop knock-in cell lines facilitates high-throughput screening which is challenging to achieve through traditional western blot assays
    • Rodent experiment capability in house enables early PK/PD tests to promptly provide clues to following degrader design for a improved drug-like properties.

UPPGRADER™

UPPGRADER is our proprietary solution that precisely discovers promising novel E3Ls with strong scientific rationales mainly based on scRNA-seq. data analysis

UPPGRADER can profile cell subtypes & disease-specific expression level & pattern of novel E3Ls, which is hard to be addressed by most other players doing tissue specific profiling

UPPBEAT™

UPPBEAT is a covalent ligand screening platform designed to discover novel ligands for the selected novel E3Ls, leveraging our proprietary probe library & strong chemoproteomics capabilities.
UPPBEAT can also be utilized to concurrently / simultaneously discover novel E3Ls and their corresponding ligands (Ligand-first approach)

While most other players focus on cysteine for covalent ligand discovery,
UPPBEAT, by targeting multiple residues beyond cysteine, widens the hit ratio for novel E3L ligands
  • A state-of-the-art LC-MS/MS in house (Vanquish Neo UHPLC + Orbitrap EclipseTM TribridTM MS) enables to routinely run chemoproteomics to deconvolute novel E3Ls.
  • Propietary covalent probe library which is expanding & organizing enables to approach multiple uncleophilic residues including Cysteine, Lysine, Tyrosine, Histidine etc.
  • Professional team with expertise on covalent ligand screening & chemoproteomics including a inventor of SuTEx (sulfur-triazole exchange chemistry) enables to effectively run UPPBEAT platform.